Tetsuya Hamaguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tetsuya Hamaguchi has a total of 239 co-authors. Here are the top co-authors by number of shared publications:
- Shunsuke Tsukamoto
Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan
5 shared publications - Yukihide Kanemitsu
Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan
5 shared publications - Atsuo Takashima
Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
4 shared publications Yasuhiro Shimada
Clinical Oncology Division, Kochi Health Sciences Center, Kochi, Japan
4 shared publications- Hideki Ueno
Department of Surgery, National Defense Medical College, Tokorozawa, Japan
3 shared publications - Junki Mizusawa
Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan
3 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Elsevier in SSRN Electronic Journal
Impact of relative dose intensity of adjuvant fluoropyrimidine monotherapy on survival outcomes in patients with stage III colorectal cancer: A pooled analysis of four randomized phase III trials (JCOG2310AS5)
Background and Purpose: Adjuvant fluoropyrimidine (FP) as well as oxaliplatin is the key drug in stage III colorectal cancer (CRC). Reduced relative dose intensity (RDI) of oxaliplatin-based chemotherapy is associated with inferior survival, but the significance of RDI reduction during FP monotherapy is unknown.Materials and Methods: We pooled individual patient data from four JCOG randomized phase III trials of patients with pathological stage III CRC who received adjuvant FP monotherapy. RFS was the primary endpoint and OS the secondary endpoint, both measured from the end of adjuvant chemotherapy. RDI was the ratio of actual-to-planned dose. Candidate RDI cut-offs (50–90%, 5% increments) were explored separately in low-risk (pT1–3N1) and high-risk (pT4 and/or N2) groups using Cox regression models.Results: Among 2,892 patients (1,798 low-risk, 1,094 high-risk), 3-year RFS was 87.5% and 71.3%, respectively (HR 2.37; 95% CI [2.03–2.78]). In the high-risk group, RDI ≥70% was associated with better 3-year RFS than RDI <70% (72.9% vs 63.5%; HR 0.66[0.51–0.85]); no significant RFS cut-off emerged in the low-risk group. For OS, RDI ≥65% was associated with better 5-year OS than OS <65% in the high-risk group (85.6% vs 76.2%; HR 0.68; [0.49–0.94]) and the similar tendency was observed in the low risk group with a cutoff of 70% (95.6% vs 90.9%; HR 0.69 [0.47–0.99]).Conclusions: Reduced RDI of adjuvant FP monotherapy was associated with poorer RFS and OS, particularly in high-risk stage III CRC. These exploratory thresholds support maintaining adequate dose intensity, pending prospective validation.
- 7 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImpact of relative dose intensity of adjuvant fluoropyrimidine monotherapy on survival outcomes in patients with stage III colorectal cancer: A pooled analysis of four randomized phase III trials (JCOG2310AS5)
Background and Purpose: Adjuvant fluoropyrimidine (FP) as well as oxaliplatin is the key drug in stage III colorectal cancer (CRC). Reduced relative dose intensity (RDI) of oxaliplatin-based chemotherapy is associated with inferior survival, but the significance of RDI reduction during FP monotherapy is unknown.Materials and Methods: We pooled individual patient data from four JCOG randomized phase III trials of patients with pathological stage III CRC who received adjuvant FP monotherapy. RFS was the primary endpoint and OS the secondary endpoint, both measured from the end of adjuvant chemotherapy. RDI was the ratio of actual-to-planned dose. Candidate RDI cut-offs (50–90%, 5% increments) were explored separately in low-risk (pT1–3N1) and high-risk (pT4 and/or N2) groups using Cox regression models.Results: Among 2,892 patients (1,798 low-risk, 1,094 high-risk), 3-year RFS was 87.5% and 71.3%, respectively (HR 2.37; 95% CI [2.03–2.78]). In the high-risk group, RDI ≥70% was associated with better 3-year RFS than RDI <70% (72.9% vs 63.5%; HR 0.66[0.51–0.85]); no significant RFS cut-off emerged in the low-risk group. For OS, RDI ≥65% was associated with better 5-year OS than OS <65% in the high-risk group (85.6% vs 76.2%; HR 0.68; [0.49–0.94]) and the similar tendency was observed in the low risk group with a cutoff of 70% (95.6% vs 90.9%; HR 0.69 [0.47–0.99]).Conclusions: Reduced RDI of adjuvant FP monotherapy was associated with poorer RFS and OS, particularly in high-risk stage III CRC. These exploratory thresholds support maintaining adequate dose intensity, pending prospective validation.
- Open Access
- 28 July 2026
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 81
Development of a simplified population pharmacokinetic–pharmacodynamic framework for exposure-informed risk stratification of neutropenia during amrubicin treatment
- 28 July 2026
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 81
Open AccessDevelopment of a simplified population pharmacokinetic–pharmacodynamic framework for exposure-informed risk stratification of neutropenia during amrubicin treatment
- Open Access
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400283
Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study
PURPOSE: The utility of capturing heterogeneity by circulating tumor DNA (ctDNA) genotyping combined with tissue analysis or applying it in a sequential manner remains uncertain. METHODS: We assessed the clinical value of ctDNA genotyping using data from 2,187 patients with advanced solid tumors enrolled in SCRUM-Japan MONSTAR-SCREEN-1, a nationwide cancer genome screening project, which examined ctDNA from longitudinally collected blood samples and tumor tissue samples (UMIN 000036749). RESULTS: Among 667 patients with both baseline ctDNA and tissue genotyping results, 51 (7.6%) had actionable biomarkers identified exclusively through ctDNA genotyping. The most frequent targets of genotype-matched therapy guided by solely ctDNA were immune checkpoint, estrogen receptor, and poly(ADP-ribose) polymerase (PARP). Comparison of objective response rates (ORRs) and progression-free survival (PFS) between patients treated based on tissue versus ctDNA alone showed no significant difference, with ORRs of 34.0% versus 23.1% ( P = .54) and a median PFS of 11.5 versus 13.8 months (hazard ratio [HR], 1.4 [95% CI, 0.72 to 2.80]), respectively. Among 924 patients undergoing sequential ctDNA genotyping, the detection of actionable biomarkers increased from 63.2% to 72.5% following subsequent ctDNA. Targets for genotype-matched therapy guided by subsequent ctDNA alone commonly included PARP, immune checkpoint, and BRAF. The ORR was 23.2% and 26.7% ( P = .75), and the median PFS was 5.2 and. 3.7 months (HR, 1.5 [95% CI, 0.79 to 2.80]) for genotype-matched therapy based on initial versus subsequent ctDNA alone, respectively. CONCLUSION: Combining ctDNA with tissue analysis, followed by sequential ctDNA assessments, effectively enhances the identification of actionable biomarkers. This strategy facilitates clinically beneficial, genetically informed therapies, underscoring its significant value in precision oncology.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400283
Open AccessBenefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study
PURPOSE: The utility of capturing heterogeneity by circulating tumor DNA (ctDNA) genotyping combined with tissue analysis or applying it in a sequential manner remains uncertain. METHODS: We assessed the clinical value of ctDNA genotyping using data from 2,187 patients with advanced solid tumors enrolled in SCRUM-Japan MONSTAR-SCREEN-1, a nationwide cancer genome screening project, which examined ctDNA from longitudinally collected blood samples and tumor tissue samples (UMIN 000036749). RESULTS: Among 667 patients with both baseline ctDNA and tissue genotyping results, 51 (7.6%) had actionable biomarkers identified exclusively through ctDNA genotyping. The most frequent targets of genotype-matched therapy guided by solely ctDNA were immune checkpoint, estrogen receptor, and poly(ADP-ribose) polymerase (PARP). Comparison of objective response rates (ORRs) and progression-free survival (PFS) between patients treated based on tissue versus ctDNA alone showed no significant difference, with ORRs of 34.0% versus 23.1% ( P = .54) and a median PFS of 11.5 versus 13.8 months (hazard ratio [HR], 1.4 [95% CI, 0.72 to 2.80]), respectively. Among 924 patients undergoing sequential ctDNA genotyping, the detection of actionable biomarkers increased from 63.2% to 72.5% following subsequent ctDNA. Targets for genotype-matched therapy guided by subsequent ctDNA alone commonly included PARP, immune checkpoint, and BRAF. The ORR was 23.2% and 26.7% ( P = .75), and the median PFS was 5.2 and. 3.7 months (HR, 1.5 [95% CI, 0.79 to 2.80]) for genotype-matched therapy based on initial versus subsequent ctDNA alone, respectively. CONCLUSION: Combining ctDNA with tissue analysis, followed by sequential ctDNA assessments, effectively enhances the identification of actionable biomarkers. This strategy facilitates clinically beneficial, genetically informed therapies, underscoring its significant value in precision oncology.
- 20 November 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (33) , 3967-3976
Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018)
PURPOSE: Doublet chemotherapy with fluoropyrimidine (FP) and oxaliplatin (OX) plus bevacizumab (BEV) is a standard regimen for unresectable metastatic colorectal cancer (MCRC). However, the efficacy of adding OX to FP plus BEV (FP + BEV) remains unclear for older patients, a population for whom FP + BEV is standard. We aimed to confirm the superiority of adding OX to FP + BEV for this population. METHODS: This open-label, randomized, phase III trial was conducted at 42 institutions in Japan. Patients with unresectable MCRC age 70-74 years with Eastern Cooperative Oncology Group performance status (ECOG-PS) 2 and those 75 years and older with ECOG-PS 0-2 were randomly assigned (1:1) to an FP + BEV arm or an OX addition (FP + BEV + OX) arm. Fluorouracil plus levofolinate calcium or capecitabine was declared before enrollment. The primary end point was progression-free survival (PFS). The study was registered in the Japan Registry of Clinical Trials (identifier: jRCTs031180145). RESULTS: Between September 2012 and March 2019, 251 patients were randomly assigned to the FP + BEV arm (n = 125) and the FP + BEV + OX arm (n = 126). The median age was 80 and 79 years in the respective arm. The median PFS was 9.4 months (95% CI, 8.3 to 10.3) in the FP + BEV arm and 10.0 months (9.0 to 11.2) in the FP + BEV + OX arm (hazard ratio [HR], 0.84 [90.5% CI, 0.67 to 1.04]; one-sided P = .086). The median overall survival was 21.3 months (18.7 to 24.3) in the FP + BEV arm and 19.7 months (15.5 to 25.5) in the FP + BEV + OX arm (HR, 1.05 [0.81 to 1.37]). The proportion of any grade ≥3 adverse events was higher in the FP + BEV + OX arm (52% v 69%). There was one treatment-related death in the FP + BEV arm and three in the FP + BEV + OX arm. CONCLUSION: No benefit of adding OX to FP + BEV as first-line treatment was demonstrated in older patients with MCRC. FP + BEV is recommended for this population.
- 20 November 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (33) , 3967-3976
Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018)
PURPOSE: Doublet chemotherapy with fluoropyrimidine (FP) and oxaliplatin (OX) plus bevacizumab (BEV) is a standard regimen for unresectable metastatic colorectal cancer (MCRC). However, the efficacy of adding OX to FP plus BEV (FP + BEV) remains unclear for older patients, a population for whom FP + BEV is standard. We aimed to confirm the superiority of adding OX to FP + BEV for this population. METHODS: This open-label, randomized, phase III trial was conducted at 42 institutions in Japan. Patients with unresectable MCRC age 70-74 years with Eastern Cooperative Oncology Group performance status (ECOG-PS) 2 and those 75 years and older with ECOG-PS 0-2 were randomly assigned (1:1) to an FP + BEV arm or an OX addition (FP + BEV + OX) arm. Fluorouracil plus levofolinate calcium or capecitabine was declared before enrollment. The primary end point was progression-free survival (PFS). The study was registered in the Japan Registry of Clinical Trials (identifier: jRCTs031180145). RESULTS: Between September 2012 and March 2019, 251 patients were randomly assigned to the FP + BEV arm (n = 125) and the FP + BEV + OX arm (n = 126). The median age was 80 and 79 years in the respective arm. The median PFS was 9.4 months (95% CI, 8.3 to 10.3) in the FP + BEV arm and 10.0 months (9.0 to 11.2) in the FP + BEV + OX arm (hazard ratio [HR], 0.84 [90.5% CI, 0.67 to 1.04]; one-sided P = .086). The median overall survival was 21.3 months (18.7 to 24.3) in the FP + BEV arm and 19.7 months (15.5 to 25.5) in the FP + BEV + OX arm (HR, 1.05 [0.81 to 1.37]). The proportion of any grade ≥3 adverse events was higher in the FP + BEV + OX arm (52% v 69%). There was one treatment-related death in the FP + BEV arm and three in the FP + BEV + OX arm. CONCLUSION: No benefit of adding OX to FP + BEV as first-line treatment was demonstrated in older patients with MCRC. FP + BEV is recommended for this population.
- Open Access
- 29 August 2024
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (10) , 1107-1114
Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group
Although treatment outcomes for metastatic colorectal cancer (mCRC) have dramatically improved over the past few decades, drug costs have also significantly increased. This study aimed to investigate which first-line treatment regimens for mCRC are actually used (frequency) in Japanese practice and at what cost. We collected data on patients with mCRC who received first-line treatment at 37 institutions of the Japan Clinical Oncology Group Colorectal Cancer Study Group from July 2021 to June 2022, and calculated the cost of regimens. The cost per month of each regimen was estimated based on standard usage, assuming a patient with a weight of 70 kg and a body surface area of 1.8 m2. We categorized the regimens into very high-cost (≥1 000 000 Japanese yen [JPY]/month), high-cost (≥500 000 JPY/month), and others (500 000JPY/month, and molecular targeted drugs being the main drivers of cost.
- 29 August 2024
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (10) , 1107-1114
Open AccessReal-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group
Although treatment outcomes for metastatic colorectal cancer (mCRC) have dramatically improved over the past few decades, drug costs have also significantly increased. This study aimed to investigate which first-line treatment regimens for mCRC are actually used (frequency) in Japanese practice and at what cost. We collected data on patients with mCRC who received first-line treatment at 37 institutions of the Japan Clinical Oncology Group Colorectal Cancer Study Group from July 2021 to June 2022, and calculated the cost of regimens. The cost per month of each regimen was estimated based on standard usage, assuming a patient with a weight of 70 kg and a body surface area of 1.8 m2. We categorized the regimens into very high-cost (≥1 000 000 Japanese yen [JPY]/month), high-cost (≥500 000 JPY/month), and others (500 000JPY/month, and molecular targeted drugs being the main drivers of cost.
- Open Access
- 2 December 2021
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 52 (2) , 114-121
Preoperative and postoperative prognostic factors of patients with stage II/III lower rectal cancer without neoadjuvant therapy in the clinical trial (JCOG0212)
The JCOG0212 trial was a randomized controlled trial comparing mesorectal excision alone to mesorectal excision with lateral lymph node dissection for stage II/III lower rectal cancer patients without clinical lateral lymph node enlargement. This study aimed to identify clinicopathological prognostic factors for relapse-free survival and overall survival of lower rectal cancer in the trial. Prospective data were selected from 663 patients with complete data. Uni and multivariable Cox regression model was applied to evaluate the preoperative and the combined preoperative and postoperative factors, respectively. Preoperative factors included age, sex, performance status, clinical T, clinical N and operative procedures. Postoperative factors included histological grade, pathological T, number of metastatic lymph nodes and number of dissected lymph nodes. No patient received neoadjuvant treatment. Regarding preoperative factors, multivariable analysis revealed that performance status 1 (vs. 0: HR 2.079, P = 0.0041) and cT4a (vs. cT2–3: HR 2.721, P = 0.0002) were independent risk factors for relapse-free survival, and those for overall survival were male (vs. female: HR 1.660, P = 0.0228) and cT4a (vs. cT2–3: HR 2.486, P = 0.0473). The only independent preoperative risk factor common for relapse-free survival and overall survival was cT4a. Taking preoperative and postoperative factors together, the number of metastatic lymph nodes was the only independent risk factor common for relapse-free survival and overall survival. Clinical stage II/III lower rectal cancer patients with cT4a should be a target of therapeutic development of neoadjuvant therapy. Postoperatively, intensive chemotherapy should be investigated for patients with more metastatic lymph nodes.
- 2 December 2021
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 52 (2) , 114-121
Open AccessPreoperative and postoperative prognostic factors of patients with stage II/III lower rectal cancer without neoadjuvant therapy in the clinical trial (JCOG0212)
The JCOG0212 trial was a randomized controlled trial comparing mesorectal excision alone to mesorectal excision with lateral lymph node dissection for stage II/III lower rectal cancer patients without clinical lateral lymph node enlargement. This study aimed to identify clinicopathological prognostic factors for relapse-free survival and overall survival of lower rectal cancer in the trial. Prospective data were selected from 663 patients with complete data. Uni and multivariable Cox regression model was applied to evaluate the preoperative and the combined preoperative and postoperative factors, respectively. Preoperative factors included age, sex, performance status, clinical T, clinical N and operative procedures. Postoperative factors included histological grade, pathological T, number of metastatic lymph nodes and number of dissected lymph nodes. No patient received neoadjuvant treatment. Regarding preoperative factors, multivariable analysis revealed that performance status 1 (vs. 0: HR 2.079, P = 0.0041) and cT4a (vs. cT2–3: HR 2.721, P = 0.0002) were independent risk factors for relapse-free survival, and those for overall survival were male (vs. female: HR 1.660, P = 0.0228) and cT4a (vs. cT2–3: HR 2.486, P = 0.0473). The only independent preoperative risk factor common for relapse-free survival and overall survival was cT4a. Taking preoperative and postoperative factors together, the number of metastatic lymph nodes was the only independent risk factor common for relapse-free survival and overall survival. Clinical stage II/III lower rectal cancer patients with cT4a should be a target of therapeutic development of neoadjuvant therapy. Postoperatively, intensive chemotherapy should be investigated for patients with more metastatic lymph nodes.
- 6 December 2019
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 14 (3) , 273-283
Developing the structure of Japan’s cancer survivorship guidelines using an expert panel and modified Delphi method
To develop consensus-based components used in the first evidence-based cancer survivorship guidelines in Japan.
- 6 December 2019
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 14 (3) , 273-283
Developing the structure of Japan’s cancer survivorship guidelines using an expert panel and modified Delphi method
To develop consensus-based components used in the first evidence-based cancer survivorship guidelines in Japan.